From the raw kratom leaf to a highly concentrated alkaloid called 7-hydroxymitragynine (7-OH).

If you have spent any time in a local Michigan smoke shop or gas station lately, you have likely seen colorful displays for 7-OH tablets, shots, and extracts. For years, companies have marketed kratom as a simple, natural leaf from Southeast Asia, a botanical supplement for energy or mild pain relief. Recently, the kratom landscape has shifted dramatically, from the raw leaf to a specific, highly concentrated alkaloid called 7-hydroxymitragynine (7-OH). 7-OH comes from the kratom plant, but it is a different beast entirely. It is significantly more potent, more addictive, and carries a much higher risk of severe withdrawal symptoms. 

At Sanford Behavioral Health, we are seeing an increasing number of individuals who began using 7-OH for anxiety or “natural” pain management, only to find themselves trapped in a cycle of dependency that mirrors traditional opioid addiction. Understanding what 7-OH is and why the legal landscape is shifting in 2026 is the first step in recognizing when it is time to seek professional help. 

What Exactly is 7-OH? 

To understand 7-OH, you first have to understand traditional kratom. Raw kratom leaf contains dozens of alkaloids, the most prevalent being mitragynine. In its natural state, mitragynine acts as a mild stimulant at low doses and a mild sedative at higher ones. However, 7-hydroxymitragynine (7-OH) is also an alkaloid, appearing only in tiny amounts in the raw plant. Manufacturers have found ways to isolate and concentrate 7-OH, or even synthesize it from mitragynine, creating semi-synthetic products that are many times more potent than the leaf itself. 

The Potency Gap

Research indicates that 7-OH is the primary driver of kratom’s opioid-like effects. It binds with high affinity to the mu-opioid receptors in the brain, the same receptors targeted by substances like morphine and oxycodone. Some pre-clinical studies suggest that 7-OH can be significantly more potent than morphine. When you move from chewing a leaf or drinking a tea to taking a concentrated 7-OH tablet, you aren’t just taking more kratom. You are moving into the realm of high-potency opioid-strength substances. 

The 2026 Legal Landscape: Banning the Gray Market

For years, 7-OH has existed in a legal gray area. Because it wasn’t explicitly listed as a controlled substance on the federal level, 7-OH was sold in Michigan gas stations and smoke shops. However, public health officials and legislators are catching up. 

Michigan House Bill 5537 

In Michigan, HB 5537 has gained traction in 2026. This legislation aims to strictly regulate or ban the sale of 7-OH concentrates and synthetic kratom derivatives. The goal is to remove these high-potency products from the reach of minors and to ensure that any “natural” kratom products left on the market are free from dangerous synthetic boosts. 

The Federal END 7-OH Act 

On a national scale, the END 7-OH Act represents a major federal push to classify 7-hydroxymitragynine as a controlled substance. The FDA has already issued numerous warnings regarding the toxicity and addiction potential of these concentrates, citing risks of liver failure, seizures, and respiratory depression. 

The reality is that the “gas station high” era of 7-OH is ending. As these substances become harder to find legally, many individuals will face the sudden, harsh reality of 7-OH withdrawal. 

The Risks of Dependency and 7-OH Withdrawal

Because 7-OH acts so powerfully on the brain’s opioid receptors, the body quickly builds tolerance. What starts as one tablet for focus or calm can quickly turn into a daily habit of taking multiple tablets just to feel “normal.” When someone stops taking 7-OH, the withdrawal symptoms are often described as being nearly identical to, and sometimes more intense than, standard opioid withdrawal.

The 7-OH Withdrawal Timeline

At Sanford Behavioral Health, we have found that withdrawal from 7-OH typically follows a predictable but grueling path: 

Hours 6–24: The onset of intense anxiety, restlessness, a runny nose, and “crawling skin.” 

Days 1–3 (The Peak): This is the most dangerous phase. Symptoms include severe muscle aches, stomach cramps, nausea, vomiting, and profound insomnia. The peak is often when individuals are at the highest risk of relapse. 

Days 4–7 (Subacute Phase): Physical symptoms begin to lessen, but extreme fatigue and emotional instability remain. 

Weeks 2+: Post-Acute Withdrawal Syndrome (PAWS) can set in, characterized by long-term depression, brain fog, and intense cravings. 

Seeking the Right Level of Care 

Quitting 7-OH cold turkey is not only painful; it can be medically risky. At Sanford Behavioral Health Detox Center, we specialize in evaluating these complex mood and substance use patterns to determine the safest clinical pathway forward. 

Subacute Detox 

For those with a heavy 7-OH habit, a subacute detox is often the first necessary step. This involves a medically supervised environment where clinicians can manage the physical symptoms of withdrawal with non-addictive medications, ensuring the patient remains hydrated, safe, and comfortable during the peak 72-hour window. At Sanford Behavioral Health, our compassionate providers are ready to address any fears about detox and ensure that the experience is safe and comfortable.

Substance Use Disorder (SUD) Residential Level of Care 

Once the physical toxins are cleared, psychological work can begin. A SUD residential level of care provides a structured environment away from the triggers of daily life. Structured living is particularly crucial for 7-OH users, as the depression and anxiety that follow withdrawal are often the primary drivers of relapse. Residential treatment allows for intensive therapy and the development of long-term coping strategies. 

Our medical professionals work closely with individuals to ensure their well-being and comfort during detox. Sanford Behavioral Health is committed to helping our patients start their journey toward a healthier, substance-free life. Our detox treatment center is 12 minutes from downtown Grand Rapids, Michigan, at the Sanford West Behavioral Health Campus. For more information about our detox program, click the link below.

References: 

Centers for Disease Control and Prevention (CDC). (2024). Notes from the Field: Kratom-Involved Overdose Deaths. 

U.S. Food and Drug Administration (FDA). (2023). FDA Warns Companies Confirmed to be Selling Products Labeled as Containing Kratom. 

National Institute on Drug Abuse (NIDA). (2023). Kratom Drug Facts. 

Michigan Legislature. (2026). House Bill 5537: Regulatory Framework for Kratom Alkaloids. 

Medical Disclaimer: This blog post is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. 7-OH, and kratom concentrates carry significant risks of dependency and physical withdrawal. Never attempt to detox from high-potency substances without professional medical supervision. If you are experiencing a medical emergency, call 911 or go to the nearest emergency room. 

All trademarks and logos are the property of their respective owners.  

Bibhas Singla, MD, MBA, FACHE, CPE, FAPA

Sanford Chief Medical Officer, Dr. Bibhas Singla, is triple board-certified in Psychiatry, Addiction Medicine, and HALM (Healthcare Administration, Leadership, and Management). He also holds industry distinctions as a FACHE (Fellow of the American College of Healthcare Executives), CPE (Certified Physician Executives), and FAPA (Fellow of the American Psychiatric Association). He has more than 15 years of experience in behavioral health, specializing in addiction treatment. Dr. Singla has cared for patients across acute, residential, and outpatient settings. He has also worked with payers and policymakers to expand access to mental health services. Look for his article series in the new year!

Related Posts

The Rise in Kratom Addiction (an RN’s Perspective)

How Do I Quit Kratom Safely?